IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.

Anti-Inflammatory Agents / pharmacology Blood Platelets / immunology CD40 Antigens / antagonists & inhibitors CD40 Ligand / antagonists & inhibitors Crohn Disease / drug therapy Humans Interleukin-1 / antagonists & inhibitors Intestinal Mucosa / drug effects Platelet Activation / drug effects Signal Transduction / drug effects
Autoimmunity CD40/CD40L axis Crohn's disease IBD IL-1 Inflammation

Journal

Archives of pharmacal research
ISSN: 1976-3786
Titre abrégé: Arch Pharm Res
Pays: Korea (South)
ID NLM: 8000036

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 29 01 2020
accepted: 21 11 2020
pubmed: 5 1 2021
medline: 12 10 2021
entrez: 4 1 2021
Statut: ppublish

Résumé

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic and multifactorial diseases that affect the intestinal tract, both characterized by recurrent inflammation of the intestinal mucosa, resulting in abdominal pain, diarrhea, vomiting and, rectal bleeding. Inflammatory bowel diseases (IBD) regroup these two disorders. The exact pathological mechanism of IBD remains ambiguous and poorly known. In genetically predisposed patients, defects in intestinal mucosal barrier are due to an uncontrolled inflammatory response to normal flora. In addition to the genetic predisposition, these defects could be triggered by environmental factors or by a specific lifestyle which is widely accepted as etiological hypothesis. The involvement of the CD40/CD40L platelet complex in the development of IBD has been overwhelmingly demonstrated. CD40L is climacteric in cell signalling in innate and adaptive immunity, the CD40L expression on the platelet cell surface gives them an immunological competence. The IL-1, a major inflammation mediator could be involved in different ways in the development of IBD. Here, we provide a comprehensive review regarding the role of platelet CD40/CD40L in the pathophysiological effect of IL-1 in the development of Crohn's disease (CD). This review could potentially help future approaches aiming to target these two pathways for therapeutic purposes and elucidate the immunological mechanisms driving gut inflammation.

Identifiants

DOI: 10.1007/s12272-020-01296-1 PMID: 33394309
pubmed: 33394309
doi: 10.1007/s12272-020-01296-1
pii: 10.1007/s12272-020-01296-1
doi:

Substances chimiques

Anti-Inflammatory Agents 0
CD40 Antigens 0
Interleukin-1 0
CD40 Ligand 147205-72-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-132

Références

Ahluwalia B, Moraes L, Magnusson MK, Ohman L (2018) Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. https://doi.org/10.1080/00365521.2018.1447597
doi: 10.1080/00365521.2018.1447597 pubmed: 29523023
Alaaeddine N, Hassan GS, Yacoub D, Mourad W (2012) CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol 2012:490148. https://doi.org/10.1155/2012/490148
doi: 10.1155/2012/490148 pubmed: 22110533
Aloui C, Prigent A, Sut C, Hamzeh-Cognasse H, Pozzetto B, Richard Y, Cognasse F, Laradi S, Garraud O (2014) The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci 15:22342–22364. https://doi.org/10.3390/ijms151222342
doi: 10.3390/ijms151222342 pubmed: 25479079
An HJ, Kim YJ, Song DH, Park BS, Kim HM, Lee JD, Paik SG, Lee JO, Lee H (2011) Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem 286:11226–11235. https://doi.org/10.1074/jbc.M110.208215
doi: 10.1074/jbc.M110.208215 pubmed: 21285457 pmcid: 3064178
Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD (2003) Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90:377–384. https://doi.org/10.1160/TH03-05-0268
doi: 10.1160/TH03-05-0268 pubmed: 12958605
Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD (2002) CD40L stabilizes arterial thrombi by a beta3 integrin—dependent mechanism. Nat Med 8:247–252. https://doi.org/10.1038/nm0302-247
doi: 10.1038/nm0302-247 pubmed: 11875495
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677. https://doi.org/10.1016/j.jacc.2009.03.076
doi: 10.1016/j.jacc.2009.03.076 pubmed: 19679244
Aouiss A, Anka Idrissi D, Kabine M, Zaid Y (2019) Update of inflammatory proliferative retinopathy: ischemia, hypoxia and angiogenesis. Curr Res Transl Med 67:62–71. https://doi.org/10.1016/j.retram.2019.01.005
doi: 10.1016/j.retram.2019.01.005 pubmed: 30685380
Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN (2014) The molecular regulation of Janus kinase (JAK) activation. Biochem J 462:1–13. https://doi.org/10.1042/BJ20140712
doi: 10.1042/BJ20140712 pubmed: 25057888 pmcid: 4112375
Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M (2010) Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59:1192–1199. https://doi.org/10.1136/gut.2009.197822
doi: 10.1136/gut.2009.197822 pubmed: 20442201
Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M (2012) Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 30(Suppl 1):82–90. https://doi.org/10.1159/000341681
doi: 10.1159/000341681 pubmed: 23075874
Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U (2002) Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 277:25032–25039. https://doi.org/10.1074/jbc.M204003200
doi: 10.1074/jbc.M204003200 pubmed: 11978801
Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23:177–189. https://doi.org/10.1016/j.blre.2009.04.001
doi: 10.1016/j.blre.2009.04.001 pubmed: 19450911 pmcid: 2720568
Bou Khzam L, Boulahya R, Abou-Saleh H, Hachem A, Zaid Y, Merhi Y (2013) Soluble CD40 ligand stimulates the pro-angiogenic function of peripheral blood angiogenic outgrowth cells via increased release of matrix metalloproteinase-9. PLoS ONE 8:e84289. https://doi.org/10.1371/journal.pone.0084289
doi: 10.1371/journal.pone.0084289 pubmed: 24358353 pmcid: 3865292
Bou Khzam L, Hachem A, Zaid Y, Boulahya R, Mourad W, Merhi Y (2013) Soluble CD40 ligand impairs the anti-platelet function of peripheral blood angiogenic outgrowth cells via increased production of reactive oxygen species. Thromb Haemost 109:940–947. https://doi.org/10.1160/TH12-09-0679
doi: 10.1160/TH12-09-0679 pubmed: 23426185
Braesch-Andersen S, Paulie S, Koho H, Nika H, Aspenstrom P, Perlmann P (1989) Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J Immunol 142:562–567
pubmed: 2463309
Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, Li Z, Mortha A, Merad M, Das A, Gevers D, McGovern DPB, Singh N, Braun J, Jacobs JP, Clemente JC, Grinspan A, Sands BE, Colombel JF, Dubinsky MC, Faith JJ (2019) Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORgammat(+) regulatory T cells and exacerbate colitis in mice. Immunity 50(212–224):e4. https://doi.org/10.1016/j.immuni.2018.12.015
doi: 10.1016/j.immuni.2018.12.015
Cabral-Marques O, Ramos RN, Schimke LF, Khan TA, Amaral EP, Barbosa Bomfim CC, Junior OR, Franca TT, Arslanian C, Carola Correia Lima JD, Weber CW, Ferreira JF, Tavares FS, Sun J, D’Imperio Lima MR, Seelaender M, Garcia Calich VL, Marzagao Barbuto JA, Costa-Carvalho BT, Riemekasten G, Seminario G, Bezrodnik L, Notarangelo L, Torgerson TR, Ochs HD, Condino-Neto A (2017) Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-gamma. J Allergy Clin Immunol 139(900–912):e7. https://doi.org/10.1016/j.jaci.2016.07.018
doi: 10.1016/j.jaci.2016.07.018
Callard RE, Armitage RJ, Fanslow WC, Spriggs MK (1993) CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 14:559–564. https://doi.org/10.1016/0167-5699(93)90188-Q
doi: 10.1016/0167-5699(93)90188-Q pubmed: 7506037
Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE (2005) CD40 ligand influences platelet release of reactive oxygen intermediates. Arter Thromb Vasc Biol 25:2428–2434. https://doi.org/10.1161/01.ATV.0000184765.59207.f3
doi: 10.1161/01.ATV.0000184765.59207.f3
Charafeddine AH, Kim EJ, Maynard DM, Yi H, Weaver TA, Gunay-Aygun M, Russell M, Gahl WA, Kirk AD (2012) Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. Am J Transpl 12:3143–3151. https://doi.org/10.1111/j.1600-6143.2012.04241.x
doi: 10.1111/j.1600-6143.2012.04241.x
Chauhan A, Adams DH (2017) Platelets are critical drivers of illness behaviors during liver inflammation. Gastroenterology 153:1188–1190. https://doi.org/10.1053/j.gastro.2017.09.029
doi: 10.1053/j.gastro.2017.09.029 pubmed: 29096821
Chen C, Li Y, Yu Z, Liu Z, Shi Y, Lewandowska U, Sobczak M, Fichna J, Kreis M (2015) Platelet activity in the pathophysiology of inflammatory bowel diseases. Curr Drug Targets 16:219–225. https://doi.org/10.2174/1389450116666150113122229
doi: 10.2174/1389450116666150113122229 pubmed: 25585124
Cho JH (2008) Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol 14:338–347. https://doi.org/10.3748/wjg.14.338
doi: 10.3748/wjg.14.338 pubmed: 18200657 pmcid: 2679123
Cibor D, Szczeklik K, Koziol K, Pocztar H, Mach T, Owczarek D (2020) Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with the varying activity of inflammatory bowel disease. Pol Arch Intern Med 130:598–606. https://doi.org/10.20452/pamw.15463
doi: 10.20452/pamw.15463 pubmed: 32589376
Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogne M, Richard Y, Garraud O (2007) Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 35:1376–1387. https://doi.org/10.1016/j.exphem.2007.05.021
doi: 10.1016/j.exphem.2007.05.021 pubmed: 17656005
Cohen SA, Gold BD, Oliva S, Lewis J, Stallworth A, Koch B, Eshee L, Mason D (2014) Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 59:516–521. https://doi.org/10.1097/MPG.0000000000000449
doi: 10.1097/MPG.0000000000000449 pubmed: 24897165
Corrigendum, Longhurst HJ, Tarzi MD, Ashworth F, Bethune C, Cale C, Dempster J, Gompels M, Jolles S, Seneviratne S, Symons C, Price A, Edgar D (2015) C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol 181:188. https://doi.org/10.1111/cei.12649
doi: 10.1111/cei.12649
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:1785–1794. https://doi.org/10.1053/j.gastro.2011.01.055
doi: 10.1053/j.gastro.2011.01.055 pubmed: 21530745
Cotton JB (1971) Use of solumedrol in pediatrics. Apropos of 45 cases. Lyon Med 225:251–254
pubmed: 5554695
Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C (2003) Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52:1435–1441. https://doi.org/10.1136/gut.52.10.1435
doi: 10.1136/gut.52.10.1435 pubmed: 12970136 pmcid: 1773814
Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C (2004) Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 172:2011–2015. https://doi.org/10.4049/jimmunol.172.4.2011
doi: 10.4049/jimmunol.172.4.2011 pubmed: 14764664
de Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13–27. https://doi.org/10.1038/nrgastro.2015.186
doi: 10.1038/nrgastro.2015.186 pubmed: 26627550
de Silva PS, Luben R, Shrestha SS, Khaw KT, Hart AR (2014) Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. Eur J Gastroenterol Hepatol 26:11–18. https://doi.org/10.1097/MEG.0b013e328365c372
doi: 10.1097/MEG.0b013e328365c372 pubmed: 24216567
Dejica DI, Manea EM (2006) Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therap Perspect Roum Arch Microbiol Immunol 65:66–74
Delaleu N, Bickel M (2004) Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. Periodontol 2000 35:42–52. https://doi.org/10.1111/j.0906-6713.2004.003569.x
doi: 10.1111/j.0906-6713.2004.003569.x pubmed: 15107057
Delmas Y, Viallard JF, Villeneuve J, Grosset C, Pasquet JM, Dechanet-Merville J, Nurden P, Pellegrin JL, Rosenbaum J, Combe C, Nurden AT, Ripoche J (2005) Platelet-associated CD154: a new interface in haemostasis and in the inflammatory reaction. Med Sci Paris 21:825–831. https://doi.org/10.1051/medsci/20052110825
doi: 10.1051/medsci/20052110825 pubmed: 16197899
Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre TM, Zimmerman GA, Weyrich AS (2005) Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122:379–391. https://doi.org/10.1016/j.cell.2005.06.015
doi: 10.1016/j.cell.2005.06.015 pubmed: 16096058 pmcid: 4401993
Di Sabatino A, Santilli F, Guerci M, Simeone P, Ardizzone S, Massari A, Giuffrida P, Tripaldi R, Malara A, Liani R, Gurini E, Aronico N, Balduini A, Corazza GR, Davi G (2016) Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-alpha treatment. Thromb Haemost 116:486–495. https://doi.org/10.1160/TH16-02-0167
doi: 10.1160/TH16-02-0167 pubmed: 27305860
Dinarello CA (1997) Interleukin-1. Cytokine Growth Factor Rev 8:253–265. https://doi.org/10.1016/s1359-6101(97)00023-3
doi: 10.1016/s1359-6101(97)00023-3 pubmed: 9620641
Dinarello CA (2004) Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4:378–385. https://doi.org/10.1016/j.coph.2004.03.010
doi: 10.1016/j.coph.2004.03.010 pubmed: 15251132
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732. https://doi.org/10.1182/blood-2010-07-273417
doi: 10.1182/blood-2010-07-273417 pubmed: 21304099 pmcid: 3083294
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652. https://doi.org/10.1038/nrd3800
doi: 10.1038/nrd3800 pubmed: 22850787 pmcid: 3644509
Dos Santos JC, Damen M, Oosting M, de Jong DJ, Heinhuis B, Gomes RS, Araujo CS, Netea MG, Ribeiro-Dias F, Joosten LAB (2017) The NOD2 receptor is crucial for immune responses towards New World Leishmania species. Sci Rep 7:15219. https://doi.org/10.1038/s41598-017-15412-7
doi: 10.1038/s41598-017-15412-7 pubmed: 29123157 pmcid: 5680260
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–172. https://doi.org/10.1111/j.1600-065X.2009.00782.x
doi: 10.1111/j.1600-065X.2009.00782.x pubmed: 19426221
Ellins SR (1985) Coyote control and taste aversion: a predation problem or a people problem? Appetite 6:272–275. https://doi.org/10.1016/S0195-6663(85)80017-9
doi: 10.1016/S0195-6663(85)80017-9 pubmed: 3000296
Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL (2003) Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19:9–19. https://doi.org/10.1016/s1074-7613(03)00177-8
doi: 10.1016/s1074-7613(03)00177-8 pubmed: 12871635
Elzey BD, Grant JF, Sinn HW, Nieswandt B, Waldschmidt TJ, Ratliff TL (2005) Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol 78:80–84. https://doi.org/10.1189/jlb.1104669
doi: 10.1189/jlb.1104669 pubmed: 15899982
Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ (1994) Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 6:267–278. https://doi.org/10.1006/smim.1994.1035
doi: 10.1006/smim.1994.1035 pubmed: 7532457
Farrukh A, Mayberry JF (2014) Is there a role for fish oil in inflammatory bowel disease? World J Clin Cases 2:250. https://doi.org/10.12998/wjcc.v2.i7.250
doi: 10.12998/wjcc.v2.i7.250 pubmed: 25032198 pmcid: 4097150
Fava F, Danese S (2011) Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 17:557–566. https://doi.org/10.3748/wjg.v17.i5.557
doi: 10.3748/wjg.v17.i5.557 pubmed: 21350704 pmcid: 3040327
Flamant M, Roblin X (2018) Inflammatory bowel disease: towards a personalized medicine. Ther Adv Gastroenterol 11:1756283X17745029. https://doi.org/10.1177/1756283X17745029
doi: 10.1177/1756283X17745029
Flaumenhaft R (2003) Molecular basis of platelet granule secretion. Arter Thromb Vasc Biol 23:1152–1160. https://doi.org/10.1161/01.ATV.0000075965.88456.48
doi: 10.1161/01.ATV.0000075965.88456.48
Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232–241. https://doi.org/10.1038/nrrheum.2010.4
doi: 10.1038/nrrheum.2010.4 pubmed: 20177398
Gachet C (2013) Molecular mechanisms of platelet activation. Bull Acad Natl Med 197:361–373. https://doi.org/10.1152/physrev.1989.69.1.58
doi: 10.1152/physrev.1989.69.1.58 pubmed: 24919366
Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010
doi: 10.1016/j.immuni.2013.11.010 pubmed: 24332029 pmcid: 3933951
Garraud O, Berthet J, Hamzeh-Cognasse H, Cognasse F (2011) Pathogen sensing, subsequent signalling, and signalosome in human platelets. Thromb Res 127:283–286. https://doi.org/10.1016/j.thromres.2010.10.015
doi: 10.1016/j.thromres.2010.10.015 pubmed: 21071069
Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR (2000) A simple classification of Crohn’s disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15. https://doi.org/10.1097/00054725-200002000-00002
doi: 10.1097/00054725-200002000-00002 pubmed: 10701144
Gaya DR, Russell RK, Nimmo ER, Satsangi J (2006) New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367:1271–1284. https://doi.org/10.1016/S0140-6736(06)68345-1
doi: 10.1016/S0140-6736(06)68345-1 pubmed: 16631883
Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F (2011) IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208:1127–1133. https://doi.org/10.1084/jem.20101712
doi: 10.1084/jem.20101712 pubmed: 21576383 pmcid: 3173242
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278:8869–8872. https://doi.org/10.1074/jbc.C200651200
doi: 10.1074/jbc.C200651200 pubmed: 12527755
Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF (2003) Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 101:2285–2293. https://doi.org/10.1182/blood-2002-09-2797
doi: 10.1182/blood-2002-09-2797 pubmed: 12433680
Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111–135. https://doi.org/10.1146/annurev.immunol.16.1.111
doi: 10.1146/annurev.immunol.16.1.111 pubmed: 9597126
Gunaydin NC, Chou J, Karaca NE, Aksu G, Massaad MJ, Azarsiz E, Ertan Y, Geha RS, Kutukculer N (2014) A novel disease-causing CD40L mutation reduces expression of CD40 ligand, but preserves CD40 binding capacity. Clin Immunol 153:288–291. https://doi.org/10.1016/j.clim.2014.05.001
doi: 10.1016/j.clim.2014.05.001 pubmed: 24845792
Hanauer SB (2017) Combination therapy for inflammatory bowel disease. Gastroenterol Hepatol NY 13:296–298
Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594. https://doi.org/10.1038/35393
doi: 10.1038/35393 pubmed: 9468137
Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA (2001) The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98:1047–1054. https://doi.org/10.1182/blood.v98.4.1047
doi: 10.1182/blood.v98.4.1047 pubmed: 11493450
Hibi T, Ogata H (2006) Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41:10–16. https://doi.org/10.1007/s00535-005-1744-3
doi: 10.1007/s00535-005-1744-3 pubmed: 16501852
Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, MacDonald JA, Beck PL (2011) NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17:1359–1372. https://doi.org/10.1002/ibd.21478
doi: 10.1002/ibd.21478 pubmed: 20872834
Hu SK, Mitcho YL, Rath NC (1988) Effect of estradiol on interleukin 1 synthesis by macrophages. Int J Immunopharmacol 10:247–252. https://doi.org/10.1016/0192-0561(88)90055-0
doi: 10.1016/0192-0561(88)90055-0 pubmed: 3263330
Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ (2003) CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92:1041–1048. https://doi.org/10.1161/01.RES.0000070111.98158.6C
doi: 10.1161/01.RES.0000070111.98158.6C pubmed: 12676820
Jandinski JJ (1988) Osteoclast activating factor is now interleukin-1 beta: historical perspective and biological implications. J Oral Pathol 17:145–152. https://doi.org/10.1111/j.1600-0714.1988.tb01515.x
doi: 10.1111/j.1600-0714.1988.tb01515.x pubmed: 3139850
Jenne CN, Urrutia R, Kubes P (2013) Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 35:254–261. https://doi.org/10.1111/ijlh.12084
doi: 10.1111/ijlh.12084 pubmed: 23590652
Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF (2013) Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis 7:e407–e413. https://doi.org/10.1016/j.crohns.2013.01.012
doi: 10.1016/j.crohns.2013.01.012 pubmed: 23403039
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, International IBDGC, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119–124. https://doi.org/10.1038/nature11582
doi: 10.1038/nature11582 pubmed: 23128233
Kaistha A, Levine J (2014) Inflammatory bowel disease: the classic gastrointestinal autoimmune disease. Curr Probl Pediatr Adolesc Health Care 44:328–334. https://doi.org/10.1016/j.cppeds.2014.10.003
doi: 10.1016/j.cppeds.2014.10.003 pubmed: 25499459
Kaminska B, Roszko-Kirpsza I, Landowski P, Szlagatys-Sidorkiewicz A, Guzinska-Ustymowicz K, Maciorkowska E (2015) Evaluation of CD40 and CD80 receptors in the colonic mucosal membrane of children with inflammatory bowel disease. Ann Agric Enviorn Med 22:695–699. https://doi.org/10.5604/12321966.1185778
doi: 10.5604/12321966.1185778
Karnell JL, Rieder SA, Ettinger R, Kolbeck R (2019) Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev 141:92–103. https://doi.org/10.1016/j.addr.2018.12.005
doi: 10.1016/j.addr.2018.12.005 pubmed: 30552917
Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL (2005) Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn’s disease. Aliment Pharmacol Ther 22:111–122. https://doi.org/10.1111/j.1365-2036.2005.02526.x
doi: 10.1111/j.1365-2036.2005.02526.x pubmed: 16011669
Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS (2018) Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol. https://doi.org/10.1016/j.clim.2018.03.004
doi: 10.1016/j.clim.2018.03.004 pubmed: 29545207
Kim TJ, Koo JS, Kim SJ, Hong SN, Kim YS, Yang SK, Kim YH (2017) Role of IL-1ra and Granzyme B as biomarkers in active Crohn’s disease patients. Biomarkers. https://doi.org/10.1080/1354750X.2017.1387933
doi: 10.1080/1354750X.2017.1387933 pubmed: 28972805
Kojok K, Akoum SE, Mohsen M, Mourad W, Merhi Y (2018) CD40L priming of platelets via NF-kappaB activation is CD40- and TAK1-dependent. J Am Heart Assoc 7:e03677. https://doi.org/10.1161/JAHA.118.009636
doi: 10.1161/JAHA.118.009636 pubmed: 30571597 pmcid: 6405550
Kojok K, Mohsen M, El Kadiry AEH, Mourad W, Merhi Y (2020) Aspirin reduces the potentiating effect of CD40L on platelet aggregation via inhibition of myosin light chain. J Am Heart Assoc 9:e013396. https://doi.org/10.1161/JAHA.119.013396
doi: 10.1161/JAHA.119.013396 pubmed: 32009527 pmcid: 7033871
Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, Kolios G, Kouroumalis EA (2004) Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16:1147–1152. https://doi.org/10.1097/00042737-200411000-00011
doi: 10.1097/00042737-200411000-00011 pubmed: 15489574
Kurti Z, Ilias A, Gonczi L, Vegh Z, Fadgyas-Freyler P, Korponay G, Golovics PA, Lovasz BD, Lakatos PL (2018) Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. BMC Gastroenterol 18:23. https://doi.org/10.1186/s12876-018-0746-6
doi: 10.1186/s12876-018-0746-6 pubmed: 29378524 pmcid: 5789702
Kusters P, Seijkens T, Burger C, Legein B, Winkels H, Gijbels M, Barthels C, Bennett R, Beckers L, Atzler D, Biessen E, Brocker T, Weber C, Gerdes N, Lutgens E (2017) Constitutive CD40 signaling in dendritic cells limits atherosclerosis by provoking inflammatory bowel disease and ensuing cholesterol malabsorption. Am J Pathol 187:2912–2919. https://doi.org/10.1016/j.ajpath.2017.08.016
doi: 10.1016/j.ajpath.2017.08.016 pubmed: 28935569
Lafage-Pochitaloff M, Herman P, Birg F, Galizzi JP, Simonetti J, Mannoni P, Banchereau J (1994) Localization of the human CD40 gene to chromosome 20, bands q12–q13.2. Leukemia 8:1172–1175
pubmed: 7518550
Lal S, Steinhart AH (2006) Antibiotic therapy for Crohn’s disease: a review. Can J Gastroenterol 20:651–655. https://doi.org/10.1155/2006/250490
doi: 10.1155/2006/250490 pubmed: 17066156 pmcid: 2660793
Lampinen M, Vessby J, Fredricsson A, Wanders A, Rorsman F, Carlson M (2019) High serum sCD40 and a distinct colonic T cell profile in ulcerative colitis associated with primary sclerosing cholangitis. J Crohns Colitis 13:341–350. https://doi.org/10.1093/ecco-jcc/jjy170
doi: 10.1093/ecco-jcc/jjy170 pubmed: 30383225
Lappas M (2013) NOD1 and NOD2 regulate proinflammatory and prolabor mediators in human fetal membranes and myometrium via nuclear factor-kappa B. Biol Reprod 89:14. https://doi.org/10.1095/biolreprod.113.110056
doi: 10.1095/biolreprod.113.110056 pubmed: 23740944
Lee JR, Koretzky GA (1998) Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes. Eur J Immunol 28:4188–4197. https://doi.org/10.1002/(SICI)1521-4141(199812)28:12%3c4188::AID-IMMU4188%3e3.0.CO;2-B
doi: 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B pubmed: 9862355
Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, Lin WY, Yeung ST, Silva HM, Li D, Hine A, Loke P, Hudesman D, Martin JC, Kenigsberg E, Merad M, Khanna KM, Littman DR (2020) Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell 180(79–91):e16. https://doi.org/10.1016/j.cell.2019.11.026
doi: 10.1016/j.cell.2019.11.026
Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, Duriez M, Brandes RP, Lutgens E, Tedgui A, Boulanger CM (2008) CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 52:1302–1311. https://doi.org/10.1016/j.jacc.2008.07.032
doi: 10.1016/j.jacc.2008.07.032 pubmed: 18929241
Levin AD, Wildenberg ME, van den Brink GR (2016) Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 10:989–997. https://doi.org/10.1093/ecco-jcc/jjw053
doi: 10.1093/ecco-jcc/jjw053 pubmed: 26896086
Li Z, Vermeire S, Bullens D, Ferrante M, Van Steen K, Noman M, Bossuyt X, Rutgeerts P, Ceuppens JL, Van Assche G (2015) Anti-tumor necrosis factor therapy restores peripheral blood B-cell subsets and CD40 expression in inflammatory bowel diseases. Inflamm Bowel Dis 21:2787–2796. https://doi.org/10.1097/MIB.0000000000000554
doi: 10.1097/MIB.0000000000000554 pubmed: 26383913
Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E (2009) The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 102:206–214. https://doi.org/10.1160/TH09-01-0029
doi: 10.1160/TH09-01-0029 pubmed: 19652870
Liu Z, Colpaert S, D’Haens GR, Kasran A, de Boer M, Rutgeerts P, Geboes K, Ceuppens JL (1999) Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 163:4049–4057
pubmed: 10491009
Liu G, Mateer SW, Hsu A, Goggins BJ, Tay H, Mathe A, Fan K, Neal R, Bruce J, Burns G, Minahan K, Maltby S, Fricker M, Foster PS, Wark PAB, Hansbro PM, Keely S (2019) Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome. Mucosal Immunol 12:862–873. https://doi.org/10.1038/s41385-019-0163-3
doi: 10.1038/s41385-019-0163-3 pubmed: 30976089
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https://doi.org/10.1038/s41421-020-0156-0
doi: 10.1038/s41421-020-0156-0 pubmed: 32194981 pmcid: 7078228
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK, International Multiple Sclerosis Genetics C, International IBDGC, Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47:979–986. https://doi.org/10.1038/ng.3359
doi: 10.1038/ng.3359
Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501. https://doi.org/10.1016/s0092-8674(01)00237-9
doi: 10.1016/s0092-8674(01)00237-9
Louis E (2018) Stopping biologics in IBD-what is the evidence? Inflamm Bowel Dis 24:725–731. https://doi.org/10.1093/ibd/izx098
doi: 10.1093/ibd/izx098 pubmed: 29548010
Ludwiczek O, Kaser A, Tilg H (2003) Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 18:142–147. https://doi.org/10.1007/s00384-002-0425-4
doi: 10.1007/s00384-002-0425-4 pubmed: 12548417
Luther J, Gala M, Patel SJ, Dave M, Borren N, Xavier RJ, Ananthakrishnan AN (2018) Loss of response to anti-tumor necrosis factor alpha therapy in Crohn’s disease is not associated with emergence of novel inflammatory pathways. Dig Sci 63:738–745. https://doi.org/10.1007/s10620-018-4932-8
doi: 10.1007/s10620-018-4932-8
Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung KA, Ohman L (2016) Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 10:943–952. https://doi.org/10.1093/ecco-jcc/jjw051
doi: 10.1093/ecco-jcc/jjw051 pubmed: 26896085
Magro F, Soares JB, Fernandes D (2014) Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol 20:4857–4872. https://doi.org/10.3748/wjg.v20.i17.4857
doi: 10.3748/wjg.v20.i17.4857 pubmed: 24803797 pmcid: 4009517
Mao L, Kitani A, Strober W, Fuss IJ (2018) The role of NLRP3 and IL-1beta in the pathogenesis of inflammatory bowel disease. Front Immunol 9:2566. https://doi.org/10.3389/fimmu.2018.02566
doi: 10.3389/fimmu.2018.02566 pubmed: 30455704 pmcid: 6230716
Monteleone M, Stow JL, Schroder K (2015) Mechanisms of unconventional secretion of IL-1 family cytokines. Cytokine 74:213–218. https://doi.org/10.1016/j.cyto.2015.03.022
doi: 10.1016/j.cyto.2015.03.022 pubmed: 25922276
Morowitz DA, Allen LW, Kirsner JB (1968) Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 68:1013–1021. https://doi.org/10.7326/0003-4819-68-5-1013
doi: 10.7326/0003-4819-68-5-1013 pubmed: 5646806
Moss AC (2015) Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep Oxf 3:63–68. https://doi.org/10.1093/gastro/gou087
doi: 10.1093/gastro/gou087 pubmed: 25567472 pmcid: 4324872
Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lopez JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF (2011) Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 117:5189–5197. https://doi.org/10.1182/blood-2010-09-299719
doi: 10.1182/blood-2010-09-299719 pubmed: 21415270 pmcid: 3109541
Naismith JH, Sprang SR (1998) Modularity in the TNF-receptor family. Trends Biochem Sci 23:74–79. https://doi.org/10.1016/s0968-0004(97)01164-x
doi: 10.1016/s0968-0004(97)01164-x pubmed: 9538693
Nakarai A, Kato J, Hiraoka S, Takashima S, Inokuchi T, Takahara M, Sugihara Y, Harada K, Okada H (2018) An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing. Gut Liver 12:420–425. https://doi.org/10.5009/gnl17236
doi: 10.5009/gnl17236 pubmed: 29945423 pmcid: 6027830
Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E (2008) Platelets and wound healing. Front Biosci 13:3532–3548
pubmed: 18508453
Ogrinc Wagner A, Friedrich V, Barthels C, Marconi P, Blutke A, Brombacher F, Brocker T (2019) Strain specific maturation of dendritic cells and production of IL-1beta controls CD40-driven colitis. PLoS ONE 14:e0210998. https://doi.org/10.1371/journal.pone.0210998
doi: 10.1371/journal.pone.0210998 pubmed: 30653608 pmcid: 6336277
Owczarek D, Rodacki T, Domagala-Rodacka R, Cibor D, Mach T (2016) Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol 22:895–905. https://doi.org/10.3748/wjg.v22.i3.895
doi: 10.3748/wjg.v22.i3.895 pubmed: 26811635 pmcid: 4716043
Pankratz S, Bittner S, Kehrel BE, Langer HF, Kleinschnitz C, Meuth SG, Gobel K (2016) The inflammatory role of platelets: translational insights from experimental studies of autoimmune disorders. Int J Mol Sci. https://doi.org/10.3390/ijms17101723
doi: 10.3390/ijms17101723 pubmed: 27754414 pmcid: 5085754
Paschou SA, Kothonas F, Lafkas A, Myroforidis A, Loi V, Terzi T, Karagianni O, Poulou A, Goumas K, Vryonidou A (2018) Favorable effect of anti-TNF therapy on insulin sensitivity in nonobese, nondiabetic patients with inflammatory bowel disease. Int J Endocrinol 2018:6712901. https://doi.org/10.1155/2018/6712901
doi: 10.1155/2018/6712901 pubmed: 29576769 pmcid: 5859792
Peppercorn MA (1993) Is there a role for antibiotics as primary therapy in Crohn’s ileitis? J Clin Gastroenterol 17:235–237
doi: 10.1097/00004836-199310000-00013
Perazzio SF, Soeiro-Pereira PV, Dos Santos VC, de Brito MV, Salu B, Oliva MLV, Stevens AM, de Souza AWS, Ochs HD, Torgerson TR, Condino-Neto A, Andrade LEC (2017) Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behcet’s disease. Arthritis Res Ther 19:235. https://doi.org/10.1186/s13075-017-1443-5
doi: 10.1186/s13075-017-1443-5 pubmed: 29052524 pmcid: 5649058
Petrovic SS, Vasiljevska MM, Obradovic SD, Tarabar DK, Doder RB, Majstorovic IJ, Petrovic MD, Magic ZM, Cikota BM, Perisic NJ, Brcerevic IA, Manojlovic NS, Rancic NK (2020) Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice. Turk J Gastroenterol 31:451–458. https://doi.org/10.5152/tjg.2020.19454
doi: 10.5152/tjg.2020.19454 pubmed: 32721916 pmcid: 7433996
Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE (2014) NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 14:9–23. https://doi.org/10.1038/nri3565
doi: 10.1038/nri3565 pubmed: 24336102
Ple H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P (2012) Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost 108:605–615. https://doi.org/10.1160/TH12-03-0153
doi: 10.1160/TH12-03-0153 pubmed: 22836280 pmcid: 3557501
Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, Barollo M, Sommariva A, D’Amico DF (2002) The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol 14:237–241. https://doi.org/10.1097/00042737-200203000-00006
doi: 10.1097/00042737-200203000-00006 pubmed: 11953687
Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, Muller-Tidow C, Kumar R, Dreger P, Luft T (2018) Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation. J Clin Oncol 36:789–800. https://doi.org/10.1200/JCO.2017.76.4662
doi: 10.1200/JCO.2017.76.4662 pubmed: 29369699
Rendu F, Brohard-Bohn B (2001) The platelet release reaction: granules’ constituents, secretion and functions. Platelets 12:261–273. https://doi.org/10.1080/09537100120068170
doi: 10.1080/09537100120068170 pubmed: 11487378
Riordan AM, Ruxton CH, Hunter JO (1998) A review of associations between Crohn’s disease and consumption of sugars. Eur J Clin Nutr 52:229–238. https://doi.org/10.1038/sj.ejcn.1600556
doi: 10.1038/sj.ejcn.1600556 pubmed: 9578334
Ripoche J (2011) Blood platelets and inflammation: their relationship with liver and digestive diseases. Clin Res Hepatol Gastroenterol 35:353–357. https://doi.org/10.1016/j.clinre.2011.02.012
doi: 10.1016/j.clinre.2011.02.012 pubmed: 21482218
Rizvi M, Pathak D, Freedman JE, Chakrabarti S (2008) CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 14:530–538. https://doi.org/10.1016/j.molmed.2008.09.006
doi: 10.1016/j.molmed.2008.09.006 pubmed: 18977174
Rosen A, Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O (1982) A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. I Des Methodologic Considerations Gastroenterol 83:541–549
Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Yost CC, Zimmerman GA, Weyrich AS (2011) Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 118:e101–e111. https://doi.org/10.1182/blood-2011-03-339705
doi: 10.1182/blood-2011-03-339705 pubmed: 21596849 pmcid: 3193274
Ruiz MA, Kaiser RL Jr, de Quadros LG, Piron-Ruiz L, Pena-Arciniegas T, Faria MAG, Siqueira RC, Pirozzi FF, Kaiser FSL, Burt RK (2017) Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease. BMC Res Notes 10:495. https://doi.org/10.1186/s13104-017-2824-1
doi: 10.1186/s13104-017-2824-1 pubmed: 28985769 pmcid: 5639601
Saluk J, Bijak M, Ponczek MB, Wachowicz B (2014) The formation, metabolism and the evolution of blood platelets. Postepy Hig Med Dosw Online 68:384–391. https://doi.org/10.5604/17322693.1098145
doi: 10.5604/17322693.1098145 pubmed: 24864090
Sandborn WJ (2016) The present and future of inflammatory bowel disease treatment. Gastroenterol Hepatol N 12:438–441
Sandborn WJ, Su C, Panes J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 377:496–497. https://doi.org/10.1056/NEJMc1707500
doi: 10.1056/NEJMc1707500 pubmed: 28767341
Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr (2017) Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology 153(77–86):e6. https://doi.org/10.1053/j.gastro.2017.03.049
doi: 10.1053/j.gastro.2017.03.049
Schaefer AK, Wastyk HC, Mohanan V, Hou CW, Lauro ML, Melnyk JE, Burch JM, Grimes CL (2017) Crohn’s disease variants of Nod2 are stabilized by the critical contact region of Hsp70. Biochemistry 56:4445–4448. https://doi.org/10.1021/acs.biochem.7b00470
doi: 10.1021/acs.biochem.7b00470 pubmed: 28792733 pmcid: 5820029
Schonbeck U, Mach F, Libby P (2000) CD154 (CD40 ligand). Int J Biochem Cell Biol 32:687–693. https://doi.org/10.1016/s1357-2725(00)00016-9
doi: 10.1016/s1357-2725(00)00016-9 pubmed: 10856699
Semple JW, Freedman J (2010) Platelets and innate immunity. Cell Mol Life Sci 67:499–511. https://doi.org/10.1007/s00018-009-0205-1
doi: 10.1007/s00018-009-0205-1 pubmed: 20016997
Semple JW, Italiano JE Jr, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11:264–274. https://doi.org/10.1038/nri2956
doi: 10.1038/nri2956 pubmed: 21436837
Senhaji N, Kojok K, Darif Y, Fadainia C, Zaid Y (2015) The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol 6:529. https://doi.org/10.3389/fimmu.2015.00529
doi: 10.3389/fimmu.2015.00529 pubmed: 26528290 pmcid: 4607859
Shanahan F, Quigley EM (2014) Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 146:1554–1563. https://doi.org/10.1053/j.gastro.2014.01.050
doi: 10.1053/j.gastro.2014.01.050 pubmed: 24486051
Sharifi A, Vahedi H, Honarvar MR, Amiriani T, Nikniaz Z, Rad EY, Hosseinzadeh-Attar MJ (2020) Vitamin D decreases CD40L gene expression in ulcerative colitis patients: a randomized, double-blinded, placebo-controlled trial. Turk J Gastroenterol 31:99–104. https://doi.org/10.5152/tjg.2020.181028
doi: 10.5152/tjg.2020.181028 pubmed: 32141817 pmcid: 7062129
Shih DQ, Targan SR (2008) Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 14:390–400
doi: 10.3748/wjg.14.390
Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900–911. https://doi.org/10.1038/nri1226
doi: 10.1038/nri1226 pubmed: 14668806
Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A-36A. https://doi.org/10.1155/2005/269076
doi: 10.1155/2005/269076 pubmed: 16151544
Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray PF (2014) Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 123:e37-45. https://doi.org/10.1182/blood-2013-12-544692
doi: 10.1182/blood-2013-12-544692 pubmed: 24523238 pmcid: 3990915
Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10:89–102. https://doi.org/10.1038/nri2691
doi: 10.1038/nri2691 pubmed: 20081871
Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, Naismith JH, Thomas D (1998) The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci 7:1124–1135. https://doi.org/10.1002/pro.5560070506
doi: 10.1002/pro.5560070506 pubmed: 9605317 pmcid: 2144015
Stokes KY, Calahan L, Hamric CM, Russell JM, Granger DN (2009) CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol 296:H689–H697. https://doi.org/10.1152/ajpheart.00962.2008
doi: 10.1152/ajpheart.00962.2008 pubmed: 19112095
Su RC, Warner EA, Breidenbach JD, Lad A, Blomquist TM, Kleinhenz AL, Modyanov N, Malhotra D, Kennedy DJ, Haller ST (2020) CD40 receptor knockout protects against microcystin-LR (MC-LR) prolongation and exacerbation of dextran sulfate sodium (DSS)-induced colitis. Biomedicines. https://doi.org/10.3390/biomedicines8060149
doi: 10.3390/biomedicines8060149 pubmed: 32998458 pmcid: 7555415
Suzuki K, Murano T, Shimizu H, Ito G, Nakata T, Fujii S, Ishibashi F, Kawamoto A, Anzai S, Kuno R, Kuwabara K, Takahashi J, Hama M, Nagata S, Hiraguri Y, Takenaka K, Yui S, Tsuchiya K, Nakamura T, Ohtsuka K, Watanabe M, Okamoto R (2018) Single cell analysis of Crohn’s disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties. J Gastroenterol. https://doi.org/10.1007/s00535-018-1437-3
doi: 10.1007/s00535-018-1437-3 pubmed: 30478723 pmcid: 6394712
Swanson GR, Sedghi S, Farhadi A, Keshavarzian A (2010) Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol 44:223–228. https://doi.org/10.1016/j.alcohol.2009.10.019
doi: 10.1016/j.alcohol.2009.10.019 pubmed: 20682190 pmcid: 3708696
Tariket S, Guerrero JA, Garraud O, Ghevaert C, Cognasse F (2019) Platelet alpha-granules modulate the inflammatory response under systemic lipopolysaccharide injection in mice. Transfusion (Paris) 59:32–38. https://doi.org/10.1111/trf.14970
doi: 10.1111/trf.14970
Tekelioglu Y, Uzun H, Sisman G (2014) Activated platelets in patients suffering from inflammatory bowel disease. Bratisl Lek Listy 115:83–85. https://doi.org/10.4149/bll_2014_018
doi: 10.4149/bll_2014_018 pubmed: 24601701
Torres MI, Rios A (2008) Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 14:1972–1980. https://doi.org/10.3748/wjg.14.1972
doi: 10.3748/wjg.14.1972 pubmed: 18395894 pmcid: 2701515
Tuvlin JA, Raza SS, Bracamonte S, Julian C, Hanauer SB, Nicolae DL, King AC, Cho JH (2007) Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis 13:573–579. https://doi.org/10.1002/ibd.20043
doi: 10.1002/ibd.20043 pubmed: 17345609
Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106:981–986. https://doi.org/10.1161/01.CIR.0000027107.54614.1A
doi: 10.1161/01.CIR.0000027107.54614.1A pubmed: 12186804
Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A (1982) A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II Result Gastroenterol 83:550–562
van Kooten C, Banchereau J (2000) CD40-CD40 ligand. J Leukoc Biol 67:2–17. https://doi.org/10.1002/jlb.67.1.2
doi: 10.1002/jlb.67.1.2 pubmed: 10647992
Vatn MH, Sandvik AK (2015) Inflammatory bowel disease. Scand J Gastroenterol 50:748–762. https://doi.org/10.3109/00365521.2015.1033000
doi: 10.3109/00365521.2015.1033000 pubmed: 25855003
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P (2017) Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389:266–275. https://doi.org/10.1016/S0140-6736(16)32537-5
doi: 10.1016/S0140-6736(16)32537-5 pubmed: 27988142
Voudoukis E, Karmiris K, Koutroubakis IE (2014) Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 20:3180–3190. https://doi.org/10.3748/wjg.v20.i12.3180
doi: 10.3748/wjg.v20.i12.3180 pubmed: 24696603 pmcid: 3964390
Wallace KL, Zheng LB, Kanazawa Y, Shih DQ (2014) Immunopathology of inflammatory bowel disease. World J Gastroenterol 20:6–21. https://doi.org/10.3748/wjg.v20.i1.6
doi: 10.3748/wjg.v20.i1.6 pubmed: 24415853 pmcid: 3886033
Weyrich AS, Lindemann S, Zimmerman GA (2003) The evolving role of platelets in inflammation. J Thromb Haemost 1:1897–1905. https://doi.org/10.1046/j.1538-7836.2003.00304.x
doi: 10.1046/j.1538-7836.2003.00304.x pubmed: 12941029
Xu XR, Liu CQ, Feng BS, Liu ZJ (2014) Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 20:3255–3264. https://doi.org/10.3748/wjg.v20.i12.3255
doi: 10.3748/wjg.v20.i12.3255 pubmed: 24695798 pmcid: 3964397
Yacoub D, Hachem A, Theoret JF, Gillis MA, Mourad W, Merhi Y (2010) Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arter Thromb Vasc Biol 30:2424–2433. https://doi.org/10.1161/ATVBAHA.110.216143
doi: 10.1161/ATVBAHA.110.216143
Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, Limami Y, Zaid N, Sadki K, Ben El Haj R, Mahir W, Belayachi L, Belefquih B, Benouda A, Cheikh A, Langlois MA, Cherrah Y, Flamand L, Guessous F, Boilard E (2020) Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. https://doi.org/10.1161/CIRCRESAHA.120.317703
doi: 10.1161/CIRCRESAHA.120.317703 pubmed: 32938299 pmcid: 7641188
Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Gueant-Rodriguez RM, Freling E, Collet-Fenetrier B, Williet N, Ziegler O, Bigard MA, Gueant JL, Peyrin-Biroulet L (2013) Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 19:66–72. https://doi.org/10.1002/ibd.22965
doi: 10.1002/ibd.22965 pubmed: 22467242
Zhang YZ, Li YY (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20:91–99. https://doi.org/10.3748/wjg.v20.i1.91
doi: 10.3748/wjg.v20.i1.91 pubmed: 24415861 pmcid: 3886036
Zhang B, Wu T, Chen M, Zhou Y, Yi D, Guo R (2013) The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett 153:58–61. https://doi.org/10.1016/j.imlet.2013.07.005
doi: 10.1016/j.imlet.2013.07.005 pubmed: 23892087
Zhao M, Gu J, Wang Z (2020) B cells in Crohn’s patients presented reduced IL-35 expression capacity. Mol Immunol 118:124–131. https://doi.org/10.1016/j.molimm.2019.12.005
doi: 10.1016/j.molimm.2019.12.005 pubmed: 31874344
Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schonbeck U, Bode C, Libby P, Peter K (2007) CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115:1571–1580. https://doi.org/10.1161/CIRCULATIONAHA.106.683201
doi: 10.1161/CIRCULATIONAHA.106.683201 pubmed: 17372166

Auteurs

Doha Anka Idrissi (D)

Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco.

Nezha Senhaji (N)

Laboratory of Genetic and Molecular Pathology, Faculty of Medicine, Hassan II University, Casablanca, Morocco.

Asmae Aouiss (A)

Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco.

Loubna Khalki (L)

Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.

Youssef Tijani (Y)

Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.

Nabil Zaid (N)

Faculty of Sciences, Department of Biology, Mohammed V University, Rabat, Morocco.

Fatima Zahra Marhoume (FZ)

Faculty of Sciences and Technology, Laboratory of Biochemistry and Neuroscience, Integrative and Computational Neuroscience Team, Hassan First University, Settat, Morocco.

Abdallah Naya (A)

Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco.

Mounia Oudghiri (M)

Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco.

Mostafa Kabine (M)

Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco.

Younes Zaid (Y)

Faculty of Sciences, Department of Biology, Mohammed V University, Rabat, Morocco. y.zaid@um5s.net.ma.
Research Center of Abulcasis, University of Health Sciences, Rabat, Morocco. y.zaid@um5s.net.ma.
ORCID: 0000-0001-8750-9106

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Sang › Cellules sanguines › Plaquettes › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD40 › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Ligand de CD40 › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Maladie de Crohn › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Monokines › Interleukine-1 › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Tissus › Membranes › Muqueuse › Muqueuse intestinale › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémostase › Activation plaquettaire › IL-1 and CD40/CD40L platelet complex: elements...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › IL-1 and CD40/CD40L platelet complex: elements...